Moderate to Severe Chronic Pain Due to Osteoarthritis of the Knee Clinical Trial
Official title:
A Randomized, Double-Blind, Placebo- and Active Controlled Study to Evaluate the Safety and Efficacy of GRT6005 in Patients With Moderate to Severe Chronic Pain Due to Osteoarthritis of the Knee
| Verified date | July 2021 |
| Source | Tris Pharma, Inc. |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
The purpose of this study is to evaluate the safety and efficacy of GRT6005 compared to placebo in patients with moderate to severe chronic pain due to osteoarthritis (OA) of the knee. This study includes a maximum 21 day Screening Period followed by a 15-week Double-blind Treatment Period and a 4-7 day Safety Follow-up period. Patients who are eligible for the Double-blind Treatment Period will be randomized to one of following treatment groups: GRT6005 high-dose range (400, 600 or 800 mcg), GRT6005 low-dose range (200, 300 or 400 mcg), oxycodone controlled release (CR) dose range (10, 20, 30, 40 or 50 mg) or placebo.
| Status | Completed |
| Enrollment | 619 |
| Est. completion date | April 4, 2014 |
| Est. primary completion date | April 2014 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 18 Years to 80 Years |
| Eligibility | Inclusion Criteria: - Diagnosis of osteoarthritis (OA) of the knee - OA knee pain present for at least 3 months - OA knee pain is the predominant (ie, most painful) pain condition - Patients require medication on at least 4 of 7 days per week to treat OA knee pain for at least 1 month. - Dissatisfaction with current OA knee pain treatment and willingness to stop taking all pain medications except for the study drug and allowed rescue medication - Average daily pain rating of at least 5 on a 0 to 10 point numerical rating scale during the 1 week prior to randomization - Female patients either postmenopausal, surgically sterile or practicing a medically acceptable method of contraception - Male patients either status post-bilateral vasectomy or using barrier contraception Exclusion Criteria: - Knee pain due to a disorder other than OA - Other pain that can confound the assessment of, or contribute to, pain at the reference knee - Surgery at the reference knee within 6 months of Screening or a history of joint replacement surgery at the reference knee - Trauma to the reference knee within 6 months of Screening with active symptoms - Steroid injections in the reference knee within 3 months of Screening - Hyaluronic acid injections in the reference knee within 6 months of Screening - Body Mass Index > 40 kg/m2 - Patient with any protocol-excluded or clinically significant medical, surgical, or medication history that would limit the patient's ability to complete or participate in this clinical trial or could confound the study assessments |
| Country | Name | City | State |
|---|---|---|---|
| United States | Site 068 | Albany | New York |
| United States | Site 009 | Albuquerque | New Mexico |
| United States | Site 045 | Altoona | Pennsylvania |
| United States | Site 034 | Anderson | South Carolina |
| United States | Site 055 | Austin | Texas |
| United States | Site 066 | Bellevue | Washington |
| United States | Site 029 | Bend | Oregon |
| United States | Site 016 | Bingham Farms | Michigan |
| United States | Site 022 | Birmingham | Alabama |
| United States | Site 051 | Birmingham | Alabama |
| United States | Site 011 | Bradenton | Florida |
| United States | Site 093 | Bristol | Tennessee |
| United States | Site 049 | Bryan | Texas |
| United States | Site 076 | Charleston | South Carolina |
| United States | Site 086 | Chicago | Illinois |
| United States | Site 081 | Chino | California |
| United States | Site 008 | Cincinnati | Ohio |
| United States | Site 079 | Cincinnati | Ohio |
| United States | Site 071 | Clearwater | Florida |
| United States | Site 069 | Cleveland | Ohio |
| United States | Site 001 | Columbus | Ohio |
| United States | Site 038 | Dallas | Texas |
| United States | Site 019 | Draper | Utah |
| United States | Site 002 | Duncansville | Pennsylvania |
| United States | Site 090 | Edgewater | Florida |
| United States | Site 030 | El Cajon | California |
| United States | Site 039 | Fair Oaks | California |
| United States | Site 061 | Fresno | California |
| United States | Site 087 | Grand Island | Nebraska |
| United States | Site 056 | Greensboro | North Carolina |
| United States | Site 017 | Hartsdale | New York |
| United States | Site 006 | High Point | North Carolina |
| United States | Site 031 | Huntsville | Alabama |
| United States | Site 041 | Indianapolis | Indiana |
| United States | Site 060 | Jacksonville | Florida |
| United States | Site 015 | Jupiter | Florida |
| United States | Site 024 | Las Vegas | Nevada |
| United States | Site 072 | Las Vegas | Nevada |
| United States | Site 052 | Marietta | Georgia |
| United States | Site 067 | Medford | Oregon |
| United States | Site 013 | Miami | Florida |
| United States | Site 083 | New Bedford | Massachusetts |
| United States | Site 003 | New Port Richey | Florida |
| United States | Site 092 | Norfolk | Virginia |
| United States | Site 021 | North Dartmouth | Massachusetts |
| United States | Site 084 | North Hollywood | California |
| United States | Site 012 | Ocala | Florida |
| United States | Site 064 | Ogden | Utah |
| United States | Site 075 | Oklahoma City | Oklahoma |
| United States | Site 074 | Omaha | Nebraska |
| United States | Site 032 | Orlando | Florida |
| United States | Site 025 | Ormond Beach | Florida |
| United States | Site 058 | Pembroke Pines | Florida |
| United States | Site 033 | Perry | Georgia |
| United States | Site 005 | Phoenix | Arizona |
| United States | Site 018 | Phoenix | Arizona |
| United States | Site 070 | Phoenix | Arizona |
| United States | Site 091 | Pinellas Park | Florida |
| United States | Site 035 | Portland | Oregon |
| United States | Site 057 | Renton | Washington |
| United States | Site 080 | Roseville | California |
| United States | Site 004 | Sacramento | California |
| United States | Site 023 | Saint Louis | Missouri |
| United States | Site 059 | Salt Lake City | Utah |
| United States | Site 040 | San Antonio | Texas |
| United States | Site 089 | San Antonio | Texas |
| United States | Site 044 | San Diego | California |
| United States | Site 007 | Sarasota | Florida |
| United States | Site 065 | Seattle | Washington |
| United States | Site 073 | Stockbridge | Georgia |
| United States | Site 048 | Toledo | Ohio |
| United States | Site 088 | Towson | Maryland |
| United States | Site 042 | Traverse City | Michigan |
| United States | Site 028 | Tucson | Arizona |
| United States | Site 043 | Tustin | California |
| United States | Site 085 | Valparaiso | Indiana |
| United States | Site 026 | Virginia Beach | Virginia |
| United States | Site 010 | Walnut Creek | California |
| United States | Site 027 | Westlake Village | California |
| United States | Site 077 | Wheaton | Maryland |
| United States | Site 082 | Wichita Falls | Texas |
| United States | Site 078 | Wilmington | North Carolina |
| United States | Site 020 | Worcester | Massachusetts |
| Lead Sponsor | Collaborator |
|---|---|
| Tris Pharma, Inc. | Forest Laboratories |
United States,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Change from baseline in the weekly average of the daily average pain rating | Baseline to end of treatment (Week 15) | ||
| Secondary | Change from baseline in the physical function subscale of the Western Ontario and McMaster University Index of Osteoarthritis Questionnaire (WOMAC) | Baseline to end of treatment (Week 15) |